文献速递临床免疫质量管理与危急值

SARS-CoV-2抗原ARCHITECT自动化免疫测定原型开发中的分析前考量

Pre-analytical considerations in the development of a prototype SARS-CoV-2 antigen ARCHITECT automated immunoassay.
PubMed 文献 · Clin Chem Lab Med · 2023-02-20

该研究评估了在高通量中心实验室进行SARS-CoV-2抗原检测时相关的分析前挑战,使用原型定性SARS-CoV-2抗原免疫测定在自动化Abbott ARCHITECT仪器上运行。研究使用 contrived 阳性和阴性标本以及去标识化的鼻和鼻咽拭子标本在转运培养基中,评估了标本和试剂 onboard 稳定性、 assay 分析性能和干扰以及临床性能。原型SARS-CoV-2抗原免疫测定在鼻和鼻咽标本中检测SARS-CoV-2具有敏感性和特异性。

要点

  • 试剂在仪器上稳定14天,无高剂量钩状效应,粘蛋白、全血、12种药物和20多种交叉反应物无干扰。
  • 标本在室温下稳定性有限,但单次冻融或-20°C长期储存(>30天)不影响标本稳定性或 assay 性能。
  • 原型 assay 特异性≥98.5%,敏感性≥89.5%,敏感性随Ct值增加而降低,与Roche Elecsys® SARS-CoV-2 Ag免疫测定报道相似。

核心结论

  • 原型SARS-CoV-2抗原ARCHITECT免疫测定在鼻和鼻咽标本中检测SARS-CoV-2具有敏感性和特异性。
  • 粘液中的内源性蛋白酶可能降解目标抗原,限制标本储存和运输时间并复杂化 assay 工作流程。

研究设计与样本

  • 使用 contrived 阳性和阴性标本以及去标识化的鼻和鼻咽拭子标本在转运培养基中。
  • 评估标本和试剂 onboard 稳定性、 assay 分析性能和干扰以及临床性能。

主要发现

  • 各种转运培养基中标本的TCID50/mL值相似。
  • 灭活阳性临床标本和病毒裂解物(USA-WA1/2020)在原型免疫测定中呈阳性。
  • 实验室内不精密度≤0.10 SD(<1.00 S/C)且CV≤10%(≥1.00 S/C)。
  • 试剂在仪器上稳定14天。
  • 对Ct 13.0的SARS-CoV-2 stock(RLU>1.0 × 10^6)未观察到高剂量钩状效应。

临床怎么用

  • 注意标本储存和运输时间,避免因粘液蛋白酶降解抗原影响检测结果。
  • 可进行单次冻融或-20°C长期储存,但室温存放时间应限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate pre-analytical challenges related to high-volume central laboratory SARS-CoV-2 antigen testing with a prototype qualitative SARS-CoV-2 antigen immunoassay run on the automated Abbott ARCHITECT instrument. METHODS: Contrived positive and negative specimens and de-identified nasal and nasopharyngeal specimens in transport media were used to evaluate specimen and reagent on-board stability, assay analytical performance and interference, and clinical performance. RESULTS: TCID50/mL values were similar for specimens in various transport media. Inactivated positive clinical specimens and viral lysate (USA-WA1/2020) were positive on the prototype immunoassay. Within-laboratory imprecision was ≤0.10 SD (<1.00 S/C) with a ≤10% CV (≥1.00 S/C). Assay reagents were stable on board the instrument for 14 days. No high-dose hook effect was observed with a SARS-CoV-2 stock of Ct 13.0 (RLU>1.0 × 106). No interference was observed from mucin, whole blood, 12 drugs, and more than 20 cross-reactants. While specimen stability was limited at room temperature for specimens with or without viral inactivation, a single freeze/thaw cycle or long-term storage (>30 days) at -20 °C did not adversely impact specimen stability or assay performance. Specificity of the prototype SARS-CoV-2 antigen immunoassay was ≥98.5% and sensitivity was ≥89.5% across two ARCHITECT instruments. Assay sensitivity was inversely correlated with Ct and was similar to that reported for the Roche Elecsys® SARS-CoV-2 Ag immunoassay. CONCLUSIONS: The prototype SARS-CoV-2 antigen ARCHITECT immunoassay is sensitive and specific for detection of SARS-CoV-2 in nasal and nasopharyngeal specimens. Endogenous proteases in mucus may degrade the target antigen, which limits specimen storage and transport times and complicates assay workflow.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Hemken PM, Israeli E, Taylor R, et al. Pre-analytical considerations in the development of a prototype SARS-CoV-2 antigen ARCHITECT automated immunoassay. Clin Chem Lab Med. 2023. PMID: 36799248. doi:10.1515/cclm-2022-1292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。